Alkermes submits new drug application for aripiprazole to treat Schizophreni
The US Food and Drug Administration (FDA) has received a new drug application (NDA) from Ireland-based Alkermes for its aripiprazole lauroxil to treat schizophrenia.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Abilify | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals | Schizophrenia